AIM IMMUNOTECH INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
AIM IMMUNOTECH INC. (AIM) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 5.10 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2026-03-27
- AIM IMMUNOTECH INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2017-09-30 was 671.05K shares, a 973.68% increase year-over-year.
- AIM IMMUNOTECH INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2016-09-30 was 62.50K shares.
- AIM IMMUNOTECH INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2025 was 5.10M shares, a 2377.66% increase from fiscal 2024.
- AIM IMMUNOTECH INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2024 was 205.88K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 5.10M shares 10-K · filed 2026-03-27 | ||||
| 2024-12-31 | 205.88K shares 10-K · filed 2026-03-27 | 20.59M shares 10-K · filed 2025-03-27 | |||
| 2017-09-30 | 671.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | 1.34M shares 10-Q · filed 2017-11-14 | |||
| 2017-06-30 | 669.62K shares 10-Q · filed 2017-08-14 | ||||
| 2016-09-30 | 62.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | 247.92K shares 10-Q · filed 2017-11-14 | |||
| 2016-06-30 | 185.42K shares 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |